Analysts await Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.44 EPS, up 359.09% or $1.58 from last year’s $-2.02 per share.

At the moment 4 analysts are watching Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), 2 rate it “Buy”, 1 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 2.00 million whilst for the year ending Dec-16, 3 analysts have a mean target of 2.10 million.

In terms of earnings per share, 2 analysts have a -0.47 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.46 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -1.87 EPS.

The biggest institutional shareholders in Bellicum Pharmaceuticals, Inc. include Baker Bros Advisors Llc which owns 5 million shares in the company valued at $98.63 million. Fidelity Management and Research Company is the second biggest holder with 2 million shares currently valued at 38.44 million whilst J.P. Morgan Investment Management Inc. has 2 million shares valued at 36.92 million.

Total shares held by institutions as of the most recent company filings are 17,915,951 with a reported 2,849,912 bought and 1,091,409 sold. These holdings make up 74.93% of the company’s outstanding shares.

Currently insiders hold 521,717 shares in the business which makes up 1.97% of shares. The biggest holder currently is Dr. David M. Spencer, PhD who owns 184,559 shares (0.70% of those outstanding), whilst Dr. Kevin M. Slawin, M.D. holds 184,206 (0.70% of shares outstanding) and Alan A. Musso holds 88,742 (0.33% of shares outstanding).

The stock increased 5.25% or $0.48 during the last trading session, hitting $14.50. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has fallen 29.86% over the past 6 months and is downtrending.